Business
Collaboration with The University of Sheffield
Collaboration with The University of Sheffield.
About this update from Physiomics Plc
[{"type":"text","content":"\n\n31 May 2023\n \nPhysiomics plc\n(\"Physiomics\" or the \"Company\")\n \nCollaboration with The University of Sheffield\n \nPhysiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, is pleased to announce that it is supporting The University of Sheffield (the \"University\") with research into an insect (Drosophila melanogaster) model of cancer treatment that could be used to screen potential new drugs prior to pre-clinical testing in more traditional mouse models of cancer. This new approach could provide important insights into the development of new cancer therapies as well as potentially reduce the number of pre-clinical animals involved in the drug development process.\nPrincipal investigator Dr Kyra Campbell of the University is the beneficiary of a three-year grant from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), awarded in December 2021, which has funded a significant programme of research at the University and other institutions where her co-investigators are based.\nThe University successfully applied for funding under the UK Research and Innovation (UKRI) Higher Education Innovation Funding (HEIF) scheme, part of which will be used to retain Physiomics for a pilot project to analyse data generated by its innovative new testing platform in order to better understand how the platform might guide later stages of pharmaceutical research into cancer therapies, including pre-clinical and human studies.\nThe project is expected to be concluded over the next two months, and a longer-term collaboration is currently under discussion.\n \nPhysiomics CEO, Dr Jim Millen commented:\n\"We are delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities. We look forward to working with Dr Campbell and her colleagues and believe that both our analytical capabilities, as well as our contacts and experience within the pharmaceutical industry, could add real value to the initiative.\"\n \nEnquiries:\n \nPhysiomics plc\nDr Jim Millen, CEO\n+44 (0)1865 784 980\n \nHybridan LLP (Broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341\n \nStrand Hanson Ltd (N...